Skip to main content

Table 3 Cause-specific hazard models predicting the risk of AD, VaD, and death [csHR (95% CI); P value] (n = 1306)

From: Short leukocyte telomeres predict 25-year Alzheimer's disease incidence in non-APOE ε4-carriers

 

Alzheimer’s disease (n = 149)

Vascular dementia (n = 96)

Death (n = 465)

Short rLTL

1.67 (0.947–2.964); P = 0.07

1.29 (0.784–2.119); P = 0.31

1.17 (0.976–1.406); P = 0.08

Long rLTL

1.38 (0.728–2.615); P = 0.32

1.12 (0.657–1.912); P = 0.67

0.85 (0.688–1.047); P = 0.12

APOE ε4-carriers

6.64 (3.651–12.087); P < 0.0001

1.54 (0.992–2.379); P = 0.05

1.32 (1.115–1.575); P = 0.001

Short rLTL/APOE ε4 interaction

0.43 (0.197–0.945); P = 0.03

Long rLTL/APOE ε4 interaction

0.42 (0.178–0.984); P = 0.04

High cholesterol (≥ 240 mg/dL)

1.49 (1.001–2.243); P = 0.05

1.15 (0.730–1.827); P = 0.53

1.06 (0.902–1.261); P = 0.45

Pulse pressure, mmHg

1.00 (0.990–1.011); P = 0.89

1.02 (1.007–1.029); P = 0.001

1.005 (1.001–1.010); P = 0.01

Plasma glucose, mg/dL

0.99 (0.984–1.001); P = 0.08

1.002 (0.997–1.008); P = 0.38

1.003 (1.002–1.005); P = 0.0002

Sedimentation rate, mm/h

1.01 (0.992–1.023); P = 0.35

1.005 (0.985–1.026); P = 0.63

1.01 (1.008–1.022); P < 0.0001

Lymphocyte proportion

0.41 (0.042–4.104); P = 0.45

0.07 (0.004–1.097); P = 0.05

0.24 (0.083–0.672); P = 0.006

Gender, male

0.46 (0.306–0.691); P = 0.0001

1.16 (0.752–1.800); P = 0.49

0.85 (0.535–1.357); P = 0.50

Age at baseline, years

1.95 (1.448–2.633); P < 0.0001

3.36 (1.999–5.639); P < 0.0001

2.96 (1.807–4.841); P = 0.02

Age squared

0.991 (0.994–0.998); P = 0.0002

0.99 (0.989–0.996); P < 0.0001

0.993 (0.990–0.997); P < 0.0001

Gender time interaction

1.26 (1.028–1.555); P = 0.001

Age at baseline time interaction

0.73 (0.606–0.885); P < 0.0001

Age squared time interaction

1.002 (1.001–1.003); P = 0.001

 

AIC = 1770

AIC = 1153

AIC = 7964

  1. AIC Akaike information criteria; APOE ε4 apolipoprotein E ε4; CI confidence interval; csHR cause-specific hazard ratio of cause-specific hazard model, accounting for competing risks; rLTL residualized leukocyte telomere length. Time from baseline, in years, was used as the time scale